Group 1 - The immunotherapy sector is experiencing a strong rebound, with companies like Zhongyuan Qihuo and Kaineng Health hitting the daily limit up [1] - Other companies in the sector, such as Jimin Health, Guanhao Bio, Chengda Pharmaceutical, Zexing Pharmaceutical, and Heyuan Bio, are also showing significant gains [1]

Group 1 - The cell immunotherapy sector experienced a significant rally in the afternoon, with Kaineng Health hitting a 20% limit up, and Jimin Health, Zhongyuan Qihe, and Nanjing Xinbai also previously reaching their limit up [1] - Sanyuan Gene saw an increase of over 10%, while Chengda Pharmaceutical and Sunshine Nuohe also followed the upward trend [1] - A recent research paper published in the journal Nature Biotechnology indicates that low-intensity ultrasound treatment can eliminate neurotoxic debris in the brains of mice induced with hemorrhagic stroke [1]

证券代码：600645 证券简称：中源协和 公告编号：2025-044 中源协和细胞基因工程股份有限公司 关于召开2025年第一次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2025年10月30 日在上海证券交易所网站和《中国证券报》、《上海证券报》、《证券时报》刊 登了《关于召开2025年第一次临时股东大会的通知》，定于2025年11月14日以现 场投票和网络投票相结合的方式召开2025年第一次临时股东大会，现将本次股东 大会的相关事项提示如下： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 股东大会召开日期：2025年11月14日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (四)现场会议召开的日期、时间和地点 (五)网络投票的系统、起止日期和投票时间。 ...

Market Overview - The Shanghai Composite Index closed at 4018.60 points, above the six-month moving average, with an increase of 0.53% [1] - The total trading volume of A-shares reached 2,194.371 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 228 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Shengli Precision (002426) with a deviation rate of 7.83% and a daily increase of 10.09% [1] - Puhua Co., Ltd. (002225) with a deviation rate of 7.49% and a daily increase of 10.07% [1] - Zhongyuan He (600645) with a deviation rate of 6.98% and a daily increase of 8.86% [1] Additional Stocks with Smaller Deviation Rates - Stocks that have just crossed the six-month moving average with smaller deviation rates include: - Hengtai Lighting (recently above the six-month line) [1] - Yilida (recently above the six-month line) [1] - Fuanna (recently above the six-month line) [1] Summary of Stocks with Deviation Rates - A detailed ranking of stocks that broke the six-month moving average includes: - Haida Co., Ltd. (300320) with a deviation rate of 6.74% and a daily increase of 8.77% [1] - Shanxi Fenjiu (600809) with a deviation rate of 6.32% and a daily increase of 6.35% [1] - Kuaiyi Elevator (002774) with a deviation rate of 6.12% and a daily increase of 7.53% [1]

Core Points - The Shanghai Composite Index is at 3998.79 points, above the six-month moving average, with a slight increase of 0.03% [1] - A total trading volume of A-shares reached 1,083.642 billion yuan today [1] - 162 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3998.79 points, reflecting a minor increase of 0.03% [1] - The total trading volume for A-shares today is 1,083.642 billion yuan [1] Stocks Exceeding Six-Month Moving Average - 162 A-shares have crossed the six-month moving average, indicating positive market sentiment [1] - Stocks with the highest deviation rates include: - Zhongyuan Qihe (8.09%) - Shunwei Co., Ltd. (4.44%) - Anglikang (4.41%) [1] Detailed Stock Data - The following stocks have notable performance metrics: - Zhongyuan Qihe: Price increased by 10.00%, with a turnover rate of 4.50% [1] - Shunwei Co., Ltd.: Price increased by 5.71%, with a turnover rate of 2.96% [1] - Anglikang: Price increased by 10.00%, with a turnover rate of 5.46% [1]

Core Viewpoint - The A-share medical sector is showing resilience with medical device stocks leading the gains, while the CXO concept is lagging behind, indicating a potential shift in market dynamics [1][3]. Group 1: Market Performance - On November 10, A-share medical stocks rose against the market trend, with Zhongyuan Xiehe hitting the daily limit and several other stocks like Jiuan Medical and Yingke Medical rising over 4% [1]. - The largest medical ETF in A-shares (512170) experienced fluctuations but was up nearly 1% at one point, attracting significant capital with a weekly inflow of 480 million yuan [1][5]. Group 2: Industry Outlook - CITIC Securities suggests that the medical device sector may be at a turning point, with opportunities for valuation recovery in individual stocks expected in the short term (2025 Q4 and 2026) [3]. - Long-term investment opportunities are anticipated from innovation, international expansion, and mergers and acquisitions, with a focus on innovative devices in areas with low domestic production rates [3]. - The medical industry is characterized as a "new quality productive force," poised for high-quality development, with expectations for improved profitability and valuation recovery [4]. Group 3: Financial Performance - In the first three quarters of this year, 45 out of 50 constituent stocks of the medical ETF (512170) reported profits, with 17 companies showing double-digit net profit growth [3]. - Notable performers include Zhaoyan New Drug and Meian Health, with net profit growth rates of 214.79% and 110.53%, respectively [4]. Group 4: Valuation Metrics - The current PE valuation of the medical ETF (512170) stands at 33.12 times, which is still below 68% of the time over the past decade, indicating potential for valuation recovery [5]. - The medical ETF has a total scale of 25.6 billion yuan, making it the largest medical ETF in the market [5].

中源协和细胞基因工程股份有限公司 2025年第一次临时股东大会 会议资料 2025 年第一次临时股东大会会议议程 现场会议时间：2025 年 11 月 14 日 14:00。 网络投票时间：采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间9:15-9:25,9:30-11:30， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开 当日 9:15-15:00。 会议地点：天津市滨海高新区华苑产业区梅苑路 12 号公司会议室。 会议出席人： 1、2025 年 11 月 7 日下午 3:00 收市后在中国证券登记结算有限责任公司上 海分公司登记在册的公司股东及股东代理人； 2、本公司董事、监事及高级管理人员； 2025 年 11 月 14 日 中源协和细胞基因工程股份有限公司 3、本公司聘请的股东大会见证律师。 会议议程： 四、审议各项议案，股东提问与解答； | 编号 | 议案内容 | | --- | --- | | 1 | 《关于续聘天健会计师事务所为公司 2025 年度审计机构的议案》 | | | 五、股东对上述议案进行投票表决； | | | 六、宣 ...

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of post-pneumonia progressive pulmonary fibrosis, marking a significant step in its drug development efforts [1][3]. Drug Information - Drug Name: VUM02 Injection - Dosage Form: Injection - Specification: 5E7 cells (10 mL) per bag - Registration Category: Class 1 therapeutic biological product - Application for: Domestic production drug registration clinical trial - Acceptance Number: CXSL2500651 - Notification Number: 2025LP02853 - Approval Conclusion: The VUM02 injection meets the requirements for drug registration and is approved to conduct clinical trials for post-pneumonia progressive pulmonary fibrosis [1]. Clinical Trial Details - The clinical trial plan submitted is a Phase IIa study evaluating the efficacy and safety of VUM02 injection in patients with post-pneumonia pulmonary fibrosis [2]. Drug Development Background - VUM02 injection is a cryopreserved cell preparation developed by the company, derived from umbilical cord mesenchymal stem cells (UC-MSCs) obtained from healthy newborns [3]. Disease Context - Progressive pulmonary fibrosis (PPF) is defined as a group of interstitial lung diseases characterized by progressive fibrosis and functional loss, with post-pneumonia progressive pulmonary fibrosis being a specific type that occurs after pneumonia [4]. - The condition is associated with various risk factors, including age, underlying diseases, immunosuppression, and smoking, and there is a significant need for effective treatment options [4]. Current Research Landscape - There is ongoing global clinical exploration of mesenchymal stem cell (MSC) therapies for various causes of pulmonary fibrosis, with existing data indicating good safety and tolerability [5]. - MSCs have the potential to address the core pathological processes of post-pneumonia progressive pulmonary fibrosis, offering a promising new treatment strategy [6]. - As of September 2025, the company has invested approximately RMB 23.52 million in related projects [6].

Core Insights - Zhongyuan Xiehe has received approval from the National Medical Products Administration for its VUM02 injection to conduct Phase IIa clinical trials for treating post-pneumonia progressive pulmonary fibrosis [1] - The company has a total of 10 indications approved for IND for VUM02, including severe COVID-19 and pneumonia, with some already in Phase II/III trials [1][2] Clinical Research Progress - VUM02 injection has completed all subject dosing in Phase I trials for idiopathic pulmonary fibrosis (IPF) and is currently organizing clinical safety and efficacy data [1] - The company’s equity stake in Beijing Sanyouli and Ze Biotechnology has led to the completion of subject enrollment for Phase II clinical trials of a human dental pulp mesenchymal stem cell injection [1] Product Development - VUM02 and VUM03 injections have collectively received approval for 11 INDs, reinforcing the company's competitive edge in the stem cell field and serving as a foundation for sustainable development [2]